BCAB vs LIN · $5.9M cap vs P/E 34, rev $33.99B
Bioatla Inc (BCAB) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Bioatla Inc (BCAB) is a biotechnology company listed on NASDAQ.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported BCAB revenue for 2023-09-30 was $0. Net income was -$33.3M. BCAB currently screens at market cap $5.9M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
BCAB currently screens at market cap $5.9M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the BCAB and LIN stock pages for the full models.
Not investment advice.